Smsbiotech Inc. has gained clearance in Australia to begin a phase I trial of its small mobile stem (SMS) cell therapy for chronic obstructive pulmonary disease (COPD).
Takeda Pharmaceutical said on Wednesday it will stop its cell therapy initiatives and seek a partner to advance its research ...
The latest chemistry news, including important research advances, business and policy trends, chemical safety practices, career guidance, and more. Current approved CAR T-cell therapy treatments rely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback